Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A sight for sore eyes
November 2019
SHARING OPTIONS:

HERZLIYA, Israel—October saw Orasis Pharmaceuticals LTD report that its CSF-1 eye drop met the primary endpoint of its Phase 2b clinical study in people with presbyopia (the inability to focus on nearby objects). Onset of this condition generally happens after the age of 40, when the lens of the eye grows stiff and loses flexibility, leading to blurred vision that impedes close proximity tasks such as reading. CSF-1 showed statistically significant improvement in distance-corrected near visual acuity of a three-line or greater gain on an eye chart, and safety and tolerability were extremely positive.
 
“We are pleased with CSF-1’s clinical performance in our Phase 2b study, as demonstrated by the positive efficacy, safety and tolerability results,” said Dr. Ron Neumann, chief medical officer of Orasis, who added “[W]e are moving forward as quickly as possible with our preparation for Phase 3.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.